The following abstracts represent the posters presented at IWWM-8 (London-2014), Session-9:

Session Chair: G. Merlini

W1: MYD88 L265P: A target for T cell based therapy of WM J. Nielsen (Canada)

W2: Clinico-Pathological Study of WM in Far East Asia N. Sekiguchi (Japan)

W3: ABT-199 (GDC-0199) Achieves Deep and Durable Responses in Patient with Heavily Pretreated WM: Preliminary Results from an Onging Phase I Study C. Tam (Australia)

W4: The Assessment of Heavy/Light chain pairs of Immunoglobulin cannot Substitute M-protein Detection in Patients with WM D. Iveta & V. Scudla (Czech Republic)

W5: The significance of 18FDG PET/CT in patients with Newly Diagnosed WM D. Iveta & V. Scudla (Czech Republic)

W6: Bing Neel Syndrome: the French experience L. Simon (France)

W7: Rare Clinical Manifestations in WM/ LPL L. Petrikkos (Greece)

W8: Borderline Cases in between IGM MM and WM. Should Cyclin-D1 Expression be used to Guide Diagnosis? L. Petrikkos (Greece)

W9: CD19 Targeted chimeric antigen modified T-cells for the treatment of WM E.L. Smith (USA)

W10: Initial Experience and Clinical Utility of a High Resolution melting Assay to detect the MYD88 L265P in Peripheral Blood and Bone marrow Aspirates in patients with LPL and Related Disorders J. Kothari (UK)

W11: Bone Involvement in Waldenström’s Macroglobulinaemia: 2 illustrative cases J. Kothari (UK)

W12: Comparison of Capillary Zone Electropheresis and Immunoturbidimetric Methods for the Quantification of Serum Monoclonal IgM in Patients with WM J. Kothari (UK)

W13: Peripheral Bing-Neel syndrome’ and other manifestations of Waldenström’s Macroglobulinaemia-related neuropathies: keeping an open mind and pursuing the precise aetiology M. Lunn (UK)

W14: Relapsed Waldenström’s macroglobulinaemia presenting as Bing-Neel Syndrome demonstrates an excellent response to IDARAM chemotherapy S. D’Sa (UK)

W15: Interplay between MYC and NK-kB Deregulation in B Cell Tumorigenesis D. Calado (UK)

W16: IMO-8400 inhibits MYD88 L265P mediated signaling and Cell growth in WM W. Jiang (USA)

W17: Heavy/Light Chain Immunoassays Measuring IgMk and IgM? provide an Alternative Method for Quantifying monocloncal IgM immunoglobulins M. Offer (UK)

W18: Microarray and Gene Expression Profiling of IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) A Greco (Italy)

W19: CD319/CS1 Expression Patterns in WM, Myeloma and MGUS: Implications for Antibody Therapy R. de Tute (UK)

W20: Use of Multi-parametric Flow Cytometry in the Diagnosis and Monitoring of WM R. de Tute (UK)

W21: Bendamustine is a well tolerated and effective rescue agent in AL amyloidosis, particularly in patients with WM P. Milani (Italy)

W22: Multi-parameter single cell phospho-filing of the BCR signaling pathway in WMW23: Gene Expression Profiling in WM: Comparison Between Asymptomatic and Symptomatic Patients K. Argyropoulos (USA)

W23: Gene Expression Profiling in WM: Comparison Between Asymptomatic and Symptomatic Patients G. Garcia Sanz (Spain)

W24: Clinical profile of single-agent modified-release oprozomib tablets in patients with WM: updated results from a multicenter, open-label, dose escalation, phase 1b/2 study I Ghobrial (USA)

W25: Bing Neel Syndrome with good response to Low Dose oral Fludarabine in Four (4) Consecutive Patients J. Vos (the Netherlands)

W26: Population based study on the impact of familial form of WM on overall survival V. Steingrimsson (Iceland)

W27: Prognostic importance of the quality of response to first line therapy in patients with WM Guidez (France)

W28: Critical growth and survival role of miR-23b/Sp1/NFkB pathway in WM M. Gkotzamanidou (USA)

W29: Spontaneous DNA Damage and DDR pathways in WM & MM: Implications for Therapy M. Gkotzamanidou (USA)

W30: Treatment Effects on IgA and IgG Hypogammaglobulinemia in WM Z. Hunter (USA)

W31: Tumor induced immunosupression in WM and MM. Marked differences in immune homeostatic balance between tumor and host D. Joshua (Australia)

W32: Diagnostic and Prognostic Significance of Constitutive and Induced pSTAT3,pSTAT5, pAKT and pERK in Plasma Cell Disorders by Phospho Flow D. Joshua (Australia)

W33: The positive effects of one hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients HJ Kim (South Korea)

W34: Characteristics and outcomes of IgM associated systemic AL amyloidosis-analysis of a prospective study [ALChemy Study] A Wechalaker (UK)

W35: Randomized Phase 2 Trial in WM Subcutaneous BCR vs. FCR for Intial Therapy of WM: a Randomized Phase II Study R. Auer (UK)

W36: Clinical Features and Survival Outcome of Young Patients with WM J. Paludo (USA)

W37: Two cases of Bing Neel Syndrome. An ongoing diagnostic and therapeutic challenge in WM E. Hatjiharissi (Greece)

W38: A Phase 1/2 study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in sCD27 signaling in patients with relapsed or refractory Waldenström’s macroglobulinemia A Thibault (Belgium)